Bli medlem
Bli medlem

Du är här


Genovis AB: Genovis publish a new share issue prospectus

Finansinspektionen (the Swedish Financial Supervisory Authority)
approved on May 13 Genovis prospectus for a new share issue with
preference for existing shareholders, the subscription period is May
23 - June 8, 2016.

Genovis AB (publ)

The Board of Directors

For more information, please contact: Fredrik Olsson, CEO, Genovis AB
Tel: 0046 (0)46 -101233


Genovis is a global company that offers enzyme products that
facilitate development and quality control of biologics to customers
in the pharmaceutical and medical technology industries. The Company
markets several enzyme products ("SmartEnzymes") in innovative
product formats all over the world.

The organization consists of Genovis AB and the wholly owned
subsidiary Genovis Inc. in the US. Genovis Inc. handles all sales of
enzyme products on the North American market and Genovis AB handles
sales in the rest of the world. Genovis shares are listed on Nasdaq
First North Stockholm and Consensus is the Company's Certified
Adviser, t: +46(0) 31 745 50 00.

This press release is a translation of the Swedish original. In the
event of any discrepancy between this translation and the Swedish
original, the Swedish version shall prevail.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.